SEC Filings

AVEXIS, INC. filed this Form 424B5 on 06/19/2017
Entire Document

Table of Contents


          The following table sets forth our cash and cash equivalents and capitalization as of March 31, 2017 on:

    an actual basis; and

    on an as adjusted basis to reflect the issuance and sale by us of $200,000,000 of shares of our common stock in this offering, and the receipt of the net proceeds from our sale of these shares, at an assumed public offering price of $70.88 per share, the last reported sale price of our common stock on The NASDAQ Global Select Market on June 16, 2017, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us (assuming no exercise of the underwriters' option to purchase additional shares).

          You should read this table together with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes appearing in our Annual Report on Form 10-K for the year ended December 31, 2016 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, which are incorporated by reference in this prospectus supplement.

  As of March 31, 2017  
As Adjusted(1)
  (in thousands, except share and per share amounts)


Cash and cash equivalents

  $ 204,454   $ 391,704  

Stockholders' equity


Undesignated preferred stock, $0.0001 par value: 10,000,000 shares authorized, no shares issued or outstanding, actual and as adjusted


Common stock, $0.0001 par value: 100,000,000 shares authorized, 27,743,174 shares issued and outstanding, actual; 100,000,000 shares authorized, 30,564,844 shares issued and outstanding, as adjusted

    3     3  

Additional paid-in capital

    392,989     580,239  

Accumulated deficit

    (171,281 )   (171,281 )

Total stockholders' equity

    221,711     408,961  

Total capitalization

  $ 221,711   $ 408,961  

Each $10.0 million increase (decrease) of shares offered by us, as set forth on the cover page of this prospectus supplement, would increase (decrease) our as adjusted additional paid-in capital, total stockholders' equity and total capitalization by approximately $9.4 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

          The number of shares of our common stock to be outstanding immediately following this offering as shown above is based on 27,743,174 shares of our common stock outstanding as of March 31, 2017 and excludes:

    2,734,141 shares of common stock issuable upon exercise of outstanding stock options as of March 31, 2017, at a weighted-average exercise price of $25.40 per share;


© AveXis, Inc. All Rights Reserved.